Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  News

News

Latest NewsCompaniesMarketsEconomy & ForexCommoditiesInterest RatesHot NewsMost Read NewsRecomm.Business LeadersCalendar 

Zogenix Inc. : Zogenix Announces Conference Call and Webcast to Present First Quarter 2013 Financial Results

share with twitter share with LinkedIn share with facebook
share via e-mail
0
05/03/2013 | 02:40pm CEST
Conference Call Scheduled for May 9, 2013 at 4:30 pm ET

SAN DIEGO, May 3, 2013 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain, today announced it will release financial results for the first quarter ended March 31, 2013, after the market closes on Thursday, May 9, 2013, and will hold a conference call on this day at 4:30 p.m. ET (1:30 p.m. PT), to discuss these financial results and provide a company update.

To access the live webcast please visit the Company's Investor Relations website at ir.zogenix.com, and to participate, please dial (866) 318-8616 (U.S.) or (617) 399-5135 (International); participant passcode: 65838569.

The conference call will be hosted by Chief Executive Officer Roger L. Hawley, President Stephen J. Farr, Ph.D., and Executive Vice President and Chief Financial Officer Ann Rhoads.

A replay of the conference call will be available beginning May 9, 2013 at 6:30 p.m. ET (3:30 p.m. PT) until May 16, 2013, by dialing (888) 286-8010 (U.S.) or (617) 801-6888 (International); passcode: 23471504. A replay of the webcast will also be accessible on the Investor Relations website for one month, through June 9, 2013.

About Zogenix

Zogenix, Inc. (Nasdaq:ZGNX), with offices in San Diego and Emeryville, California, is a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain. Zogenix's first commercial product, SUMAVEL® DosePro® (sumatriptan injection) Needle-free Delivery System, was launched in January 2010 for the acute treatment of migraine and cluster headache. Zogenix's lead investigational product candidate, Zohydro™ ER (hydrocodone bitartrate), is an oral, extended-release formulation of various strengths of hydrocodone, without acetaminophen, intended for administration every 12 hours for around the clock management of moderate to severe chronic pain. In May 2012, Zogenix submitted to the FDA a New Drug Application for Zohydro ER. Zogenix's second investigational product candidate, Relday™, is a proprietary, long-acting injectable formulation of risperidone for the treatment of schizophrenia; an investigational new drug application was submitted to the FDA in May 2012. For additional information, please visit www.zogenix.com.

CONTACT: INVESTORS:
         Zack Kubow | The Ruth Group
         646.536.7020 | zkubow@theruthgroup.com

         MEDIA:
         Caitlin Cox | The Ruth Group
         646.536.7033 | ccox@theruthgroup.com
Zogenix
distributed by
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news
Date Title
07:19p LAMB WESTON : employees say anti-union firm is intimidating them at work
07:06p WAL MART STORES : Transformers movie characters to visit Wichita Walmart stores
07:05p OFFICE OF PRESIDENT OF GOVERNMENT OF KENYA : PRESIDENT’S GOODWILL MESSAGE TO MUSLIM FAITHFUL IN KENYA AS THEY MARK EID UL FITR CELEBRATIONS
07:04p INTESA SANPAOLO : Italy giving 5.2B euros in resources to keep 2 banks open
07:04p HOME DEPOT : Confirmed tornado rips through Home Depot parking lot in South Jersey
06:52p AIRASIA BERHAD : Flight turned A pilot turned around an AirAsia flight on its way from Perth to Malaysia due to a technical problem with the plane. Flight D7237 departed ...
06:52p CITIGROUP : Stores want bigger slice of Domino’s pizza
06:51p QANTAS AIRWAYS : American Air to come back stronger
06:51p MORGAN STANLEY : Britain’s financial power already on the wane
06:48p HONDA MOTOR : Middletown man in collision in which Newark man died
Latest news
Advertisement
Hot News 
18.96%IMAGINATION TECHNOLOGIES : U.K. Chip Designer Puts Itself on Block -- WSJ
-5.33%GLOBAL LOGISTIC PROPERTIES : Says It Remains in Talks With Shortlisted Bidders
-12.28%BlackBerry misses sales forecasts, shares tumble
-1.23%Harley-Davidson Discussing Purchase of Italian Rival Ducati From VW
1.40%BOEING : Is Top Seller at Paris Air Show -- WSJ
Most Read News
12:22p Sears Canada to close stores, cut jobs in restructuring
11:57a INTESA SANPAOLO : Italy to appoint special administrators for Veneto lenders
06/24 Lufthansa wants to help, not take over, Air Berlin - Bild
06/24 Internal dossier criticises Audi top management - Bild
06/24 INFOSYS : to settle visa row with New York State for $1 million settlement
Most recommended articles
12:22p Sears Canada to close stores, cut jobs in restructuring
12:00p INTESA SANPAOLO : board tasks CEO with completing purchase of Veneto banks' assets
09:15aDJAPPLE : In 10 Years, Your iPhone Won't Be a Phone Anymore
08:15aDJQuakes Giving Dutch Province 'A Makeover We Don't Want'
07:15aDJBANCO SANTANDER : Bankers Have Less to Fear from 'Stress Tests'